Special Issue "Therapies of Uveal Melanoma"
Deadline for manuscript submissions: closed (30 May 2023) | Viewed by 7140
Institut Curie, Institut national de la santé et de la recherche médicale (INSERM), PSL Research University, U830, 75005 Paris, France
Interests: gynecological and ocular cancer
Uveal melanoma (UM) is the most common intraocular malignant tumor in adults. Primary tumors are treated with conservative strategies, such as brachytherapy or proton-beam therapy but sometimes require enucleation. Even if local treatment is very efficient, up to 50% of patients will eventually suffer metastatic recurrence. Risk of metastatic recurrence can be estimated with TNM staging, as well as transcriptomic or genomic signatures. When metastatic, UM is associated with poor prognosis. Until recently with the positive results of two clinical trials with tebentafusp, no treatment had previously shown clinical efficiency on metastatic UMs. Various inhibitors have been tested in clinical trials to target GNAQ/GNA11-activating mutations, including MAPK and PKC, with limited, if any, clinical benefit. Cytotoxic drugs and immune checkpoint inhibitors are associated with limited activity, although some exceptional responder patients have been reported.
This Special Issue will focus on the treatment of primary, as well as metastatic, UM patients. We will not only accept papers on the different, current and future therapeutic options, but also on the development of new targets and new models, as well as on the supportive and psychological care of our patients.
Examples of eligible themes:
Diagnosis and Prognosis
Pathology including Molecular Pathology
Prognostication and psychological consequences
Local treatment approaches
Radiotherapy / Protontherapy
Consequences including radio-induced retinopathies and psychological consequences
Follow-up of UM patients after local treatment
Treatment of metastatic disease
Liver-directed therapies including chemoembolization
Supportive care including palliative and psychological care
Dr. Manuel Rodrigues
Dr. Sergio Roman-Roman
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Uveal melanoma (UM)
- Diagnosis and prognosis
- Psychological consequences
- Local treatment approaches
- Treatment of metastatic disease
- Supportive care